Project Update27 Jul 2026, 05:40 pm
Senores Pharma: IPO Proceeds Monitoring Report for Q2 2026
AI Summary
Senores Pharmaceuticals Ltd has submitted its Monitoring Agency Report for the quarter ended June 30, 2026, concerning the utilization of its Initial Public Offering (IPO) proceeds. The report, issued by CARE Ratings Limited, confirms that the utilization of funds is generally in line with the IPO's stated objectives. However, it notes ongoing delays in the implementation of one object, which was scheduled for completion by FY26. Prior delays in two other objects were resolved in Q1FY26. The company has sought shareholder approval for variations in project objectives. The report has been reviewed by the Audit Committee and taken on record by the Board of Directors.
Key Highlights
- Monitoring Agency Report for IPO proceeds utilization submitted.
- Report covers quarter ended June 30, 2026.
- Ongoing delay noted for one project; prior delays resolved.
- Company seeking shareholder approval for project variations.
- Report reviewed by Audit Committee and Board of Directors.
Price Impact
More from SENORES